(Q30890582)

20 August 2017

0 references

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma (English)

1 reference

20 August 2017

phase II clinical trial

0 references

phase III clinical trial

0 references

0 references

1 reference

1

0 references

Caroline Robert

3

object named as

Caroline Robert

0 references

Tai-Tsang Chen

object named as

Tai-Tsang Chen

8

0 references

Jedd D. Wolchok

10

object named as

Jedd D Wolchok

1 reference

20 August 2017

2

F Stephen Hodi

1 reference

20 August 2017

Jeffrey S Weber

4

1 reference

20 August 2017

Kim Margolin

5

1 reference

20 August 2017

Omid Hamid

6

1 reference

20 August 2017

Debra Patt

7

1 reference

20 August 2017

David M Berman

9

1 reference

20 August 2017

language of work or name

English

0 references

publication date

9 February 2015

1 reference

Journal of Clinical Oncology

20 August 2017

1 reference

20 August 2017

33

1 reference

20 August 2017

1889-1894

1 reference

20 August 2017

17

1 reference

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5089162

Nivolumab plus ipilimumab in advanced melanoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5089162

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5089162

Raising the bar: the curative potential of human cancer immunotherapy.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5089162

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5089162

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5089162

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5089162

Systematic review of medical treatment in melanoma: current status and future prospects.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5089162

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5089162

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5089162

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5089162

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5089162

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5089162

Final version of 2009 AJCC melanoma staging and classification

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5089162

Immunostimulatory monoclonal antibodies for cancer therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5089162

High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5089162

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5089162

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

25 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5089162

25 November 2018

Identifiers

DOI

10.1200/JCO.2014.56.2736

1 reference

20 August 2017

1 reference

20 August 2017

1 reference